Pharma & Biotech

Bio Green Med Solution, Inc., the post-restructuring entity formerly known as Cyclacel Pharmaceuticals, has entered a measured, quiet phase as...

The Chapter 7 proceedings for Athersys, the developer behind MultiStem, are entering their tail end in a U.S. bankruptcy court...

BridgeBio Pharma announced yesterday the successful completion of the pivotal Phase 3 PROPEL 3 study evaluating Infigratinib. The data demonstrate...

Atreca, the biotechnology firm, is in the final phase of its wind-down and formal dissolution. Shareholders had already endorsed this...

Investors holding shares of Novan have reached the end of the line. The company's stock is now effectively worthless, a...

Biotechnology firm Rallybio is navigating a significant operational transition. Having recently adjusted its capital structure to secure its stock exchange...

While Eli Lilly continues to generate headlines and record earnings with its blockbuster weight-loss drugs, the pharmaceutical giant's leadership is...

Following the failure of its lead clinical candidate, Quince Therapeutics has initiated a formal review of its strategic options. The...

Investor attention turns to Vanda Pharmaceuticals today as the company prepares to release its fourth-quarter and full-year 2025 financial statements...

AIM ImmunoTech has initiated a critical financing effort to support its ongoing clinical programs. The biotechnology firm announced the commencement...